On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- MHLW, Daiichi Sankyo Call for Proper Use of Denosumab after 3 Deaths in US
May 21, 2012
- DPJ Committee Approves Proposal to Reform Preventive Vaccination System
May 18, 2012
- DPJ Subcommittee Proposes Inclusion of 3 Subsidized Vaccines in Regular Vaccination Programs
May 16, 2012
- Gov’t to Begin Operating “Drug Discovery Network” This FY with Initial Focus on Seeds for Anticancer Agents
May 14, 2012
- DPJ’s PAL Subcommittee Calls for Establishment of Third-Party Organization within MHLW
May 11, 2012
- Expert Subcommittee on Cost-Effectiveness Assessments to Begin Discussions this Month: Policy Planning Director Sakoi
May 11, 2012
- Japan’s Application for Membership in PIC/S Reported: PIC/S General Meeting
May 11, 2012
- Risk Management Plans Must Be Submitted By 1 Month Prior to Launch: MHLW Notification
May 8, 2012
- Gov’t, Industry Leaders to Meet on May 10 for Second Dialogue on 5-Year Medical Innovation Strategy
May 8, 2012
- MHLW to Ease GCP Ordinance in Line with ICH-GCP, Promote Clinical Trials
May 7, 2012
- 1st Committee on Drugs Recommends Approval for MTPC’s DPP-4 Inhibitor Teneligliptin
May 7, 2012
- Interview with PMDA Chief Executive Tatsuya Kondo (2)
May 2, 2012
- Interview with PMDA Chief Executive Tatsuya Kondo (1)
May 1, 2012
- DPJ's PAL Subcommittee to Finalize Reform Proposal in May, Some Recommendations to Be Reflected in Economy Revival Strategy
April 27, 2012
- CSIMC to Establish Expert Subcommittee on Cost-Effective Assessments, 1st Meeting Scheduled in June
April 26, 2012
- IPV Vaccination Set to Begin in September; Adequate Supplies Expected
April 25, 2012
- Drug Discovery Support Network to Be Coordinated by NIBIO: 5-Year Strategy for Medical Innovation
April 25, 2012
- Medicoeconomic Assessment Should Initially Be Used in Reevaluating Existing Drugs: Dr Fukuda of NIPH
April 24, 2012
- HTA Should Be Used for NHI Drug Pricing, Not Reimbursement: Prof. Endo at DPJ Hearings
April 24, 2012
- PAFSC’s 2nd Committee Recommends Approval for Astellas’ Prostate Cancer Treatment, Japan's First IPV
April 23, 2012
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…